Welcome to chemicalbook!
Chinese English Japanese Germany Korea
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook CAS DataBase List Nilotinib

Nilotinib synthesis

8synthesis methods
Nilotinib, also known as AMN107, is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia. Structurally related to imatinib, it was developed based on the structure of the Abl-imatinib complex to address imatinib intolerance and resistance. Nilotinib is a selective Bcr-Abl kinase inhibitor that is 10-30 fold more potent than imatinib in inhibiting Bcr-Abl tyrosine kinase activity and proliferation of Bcr-Abl expressing cells. Nolitinib was developed by Novartis and is sold under the trade name Tasigna.
Synthetic Routes
  • ROUTE 1
  • 202112074126634158.jpg

    Ueda, Satoshi; Su, Mingjuan; Buchwald, Stephen L. Completely N1-selective palladium-catalyzed arylation of unsymmetric imidazoles: application to the synthesis of nilotinib. Journal of the American Chemical Society. Volume 134. Issue 1. Pages 700-706. 2012.

  • ROUTE 2
  • 202112070936873635.jpg

    Breitenstein, Werner; Furet, Pascal; Jacob, Sandra; Manley, Paul William. Preparation of pyrimidinylaminobenzamides as inhibitors of protein kinases, in particular tyrosine kinases for treating neoplasm, especially leukemia. Assignee Novartis A.-G., Switz.; Novartis Pharma G.m.b.H. WO 2004005281. (2004).

  • ROUTE 3
  • 202112074537304788.jpg

    Pan, Xiaoyan; Lu, Wen; Li, Pengfei; Wang, Fang; Wang, Chen; Hu, Zhigang; Zhang, Jie. A novel and facile synthetic approach for tasigna. Medicinal Chemistry. Volume 8. Issue 5. Pages 985-989. 2012.

  • ROUTE 4
  • 202112079193134938.jpg

    Zhang, Jie; He, Langchong; Pan, Xiaoyan; Lu, Wen; Wang, Chen; Wang, Sicen; Li, Xiling. Process for preparation of Nilotinib. Assignee Xi'an Jiaotong University, Peop. Rep. China. CN 102321073. (2012).

  • ROUTE 5
  • 202112070121844173.jpg

    Chen, Yongjiang; Wang, Lihua; Zhou, Hong; Wang, Congzhan. Synthesis of nilotinib. Zhongguo Yiyao Gongye Zazhi. Volume 40. Issue 6. Pages 401-403, 411. 2009.

  • ROUTE 6
  • 202112075574179011.jpg

    Liu, Xuejun; Chen, Xiaodong; Hao, Lu; Wu, Feng. Preparation method of nilotinib. Assignee Shanghai Fuxingxingtai Pharmaceutical Technology Co., Ltd., Peop. Rep. China. CN 109666023. (2019).

  • ROUTE 7
  • 202112078993166837.jpg

    Kompella, Amala; Bhujanga Rao, Adibhatla Kali Satya; Rachakonda, Sreenivas; Gampa, Venugopala Krishna; Nannapaneni, Venkaiah Chowdary. Process for the preparation of nilotinib hydrochloride. Assignee Natco Pharma Limited, India. EP 2626355. (2013).

  • ROUTE 8
  • 202112076840509941.jpg

    Huang, Wei-Sheng; Shakespeare, William C. An efficient synthesis of nilotinib (AMN107). Synthesis. Issue 14. Pages 2121-2124. 2007.

  • ROUTE 9
  • 202112073116163232.jpg

    Yeori, Adi; Wang, Yanling; Li, Jie; Zhu, Jirang; Lifshitz-Liron, Revital; He, Xungui. Process for preparation of Nilotinib and intermediates. Assignee Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc. WO 2010060074. (2010).

  • ROUTE 10
  • 202112076201321510.jpg

    McKenna, Joseph; Shieh, Wen-Chung. Process for the synthesis of pyrimidine derivative. Assignee Novartis A.-G., Switz.; Novartis Pharma G.m.b.H. WO 2006135641. (2006).

202112074126634158.jpg

Ueda, Satoshi; Su, Mingjuan; Buchwald, Stephen L. Completely N1-selective palladium-catalyzed arylation of unsymmetric imidazoles: application to the synthesis of nilotinib. Journal of the American Chemical Society. Volume 134. Issue 1. Pages 700-706. 2012.

641571-11-1 Synthesis
3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)aniline

641571-11-1
335 suppliers
$9.00/1g

641569-94-0 Synthesis
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid

641569-94-0
240 suppliers
$7.00/250mg

-

Yield:641571-10-0 94%

Reaction Conditions:

Stage #1: 4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzoic acidwith thionyl chloride in 1-methyl-pyrrolidin-2-one at 60; for 1.25 h;
Stage #2: 5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)-benzenamine in 1-methyl-pyrrolidin-2-one at 90; for 3 h;Product distribution / selectivity;

Steps:

12

Example 12; Preparation of NilotinibTo 1 L glass reactor was added the compound of formula 4-methyl-3-{[4-(pyridin-3-yl) pyrimidin-2-yl]amino}benzoic acid of formula X (80.0 g, 0.26 mol), and N-Methyl-pyrrolidone (400 mL). The mixture was heated to 60° C., then SOCl2 (24 mL, 0.33 mol) was added during 15 minutes. The resulted mixture was stirred at 60° C. for 1 h. A compound of formula I (69.2 g, 0.29 mol) was added and the reaction mixture was stirred and heated to 90° C. for 3 h. Water (500 mL) was added and the solution was heated to 80° C. NaOH 47% solution (65 mL) was added until pH 11-12. Then, the suspension was cooled to 40° C. and stirred at this temperature for 2 hours, filtered under reduced pressure at 40° C., and washed with 500 mL H2O to yield a beige solid. This material was slurried in water (1 L) at 40° C. for 1 h, filtered, washed with water (500 mL), and dried under vacuum at 50° C. to obtain 135.25 g of Nilotinib base with 94% yield. (95.8% assay, 99.46% purity).

References:

US2010/16590,2010,A1 Location in patent:Page/Page column 20

641571-11-1 Synthesis
3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)aniline

641571-11-1
335 suppliers
$9.00/1g

917392-54-2 Synthesis
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid methyl ester

917392-54-2
122 suppliers
inquiry

Nilotinib Related Search: